<p style='font-style: italic; text-align: center; margin-top: 12pt; margin-btoom: 6pt'>Article 10</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>1.  In the case of devices intended for clinical investigations, the manufacturer or <a href='http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32007L0047:EN:NOT'\
    title='32007L0047: REPLACED'\
    target='_blanc'>\
    <span style='font-weight: bold'>►M4</span>\
</a> the<span style='font-weight: bold'> ◄ </span> authorized representative established in the Community shall, at least 60 days before the commencement of the investigations, submit the statement referred to in Annex 6 to the competent authorities of the Member State in which the investigations are to be conducted.</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>2.  The manufacturer may commence the relevant clinical investigations at the end of a period of 60 days after notification, unless the competent authorities have notified him within that period of a decision to the contrary, based on considerations of public health or public order.</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; font-weight: bold; text-align: left; margin-top: 6pt; margin-bottom: 0pt'>\
<a href='http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32007L0047:EN:NOT'\
    title='32007L0047: REPLACED'\
    target='_blanc'>▼M4</a>\
</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>Member States may, however, authorise manufacturers to start the clinical investigations in question before the expiry of the 60-day period, provided that the ethics committee concerned has issued a favourable opinion with respect to the investigation programme in question including its review of the clinical investigation plan.</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; font-weight: bold; text-align: left; margin-top: 6pt; margin-bottom: 0pt'>\
<a href='http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31993L0042:EN:NOT'\
    title='31993L0042: INSERTED'\
    target='_blanc'>▼M1</a>\
</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>2a.  The authorization referred to in the second subparagraph of paragraph 2 may be subject to approval by the competent authority.</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; font-weight: bold; text-align: left; margin-top: 6pt; margin-bottom: 0pt'>\
<a href='http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32007L0047:EN:NOT'\
    title='32007L0047: REPLACED'\
    target='_blanc'>▼M4</a>\
</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>3.  The Member States shall, if necessary, take the appropriate steps to ensure public health and public policy. Where a clinical investigation is refused or halted by a Member State, that Member State shall communicate its decision and the grounds therefor to all Member States and the Commission. Where a Member State has called for a significant modification or temporary interruption of a clinical investigation, that Member State shall inform the Member States concerned about its actions and the grounds for the actions taken.</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; font-weight: bold; text-align: left; margin-top: 6pt; margin-bottom: 0pt'>\
<a href='http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32007L0047:EN:NOT'\
    title='32007L0047: INSERTED'\
    target='_blanc'>▼M4</a>\
</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>4.  The manufacturer or his authorised representative shall notify the competent authorities of the Member States concerned of the end of the clinical investigation, with a justification in case of early termination. In the case of early termination of the clinical investigation on safety grounds this notification shall be communicated to all Member States and the Commission. The manufacturer or his authorised representative shall keep the report referred to in point 2.3.7 of Annex 7 at the disposal of the competent authorities.</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>5.  Clinical investigations shall be conducted in accordance with the provisions of Annex 7. The measures designed to amend non-essential elements of this Directive relating to the provisions on clinical investigation in Annex 7 shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 6(4).</p>\
<p style='font-style: italic; text-align: center; margin-top: 12pt; margin-btoom: 6pt'>Article 10a</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>1.  Any manufacturer who, under his own name, places devices on the market in accordance with the procedure referred to in Article 9(2) shall inform the competent authorities of the Member State in which he has his registered place of business of the address of the registered place of business and the description of the devices concerned.</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>1.  Member States may request to be informed of all data allowing for the devices to be identified together with the label and the instructions for use when the devices are put into service within their territory.</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>2.  Where a manufacturer who places a device on the market under his own name does not have a registered place of business in a Member State, he shall designate a single authorised representative in the European Union.</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>2.  For devices referred to in the first subparagraph of paragraph 1 the authorised representative shall inform the competent authority of the Member State in which he has his registered place of business of all details as referred to in paragraph 1.</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>3.  The Member States shall on request inform the other Member States and the Commission of the details referred to in the first subparagraph of paragraph 1 given by the manufacturer or authorised representative.</p>\
<p style='font-style: italic; text-align: center; margin-top: 12pt; margin-btoom: 6pt'>Article 10b</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>1.  Regulatory data in accordance with this Directive shall be stored in a European databank accessible to the competent authorities to enable them to carry out their tasks relating to this Directive on a well-informed basis.</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>1.  The databank shall contain the following:</p>\
<div style='margin-left: 30pt; text-indent: -30pt'>\
    <p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>(a)<span style='word-spacing: 18pt'> </span>data relating to certificates issued, modified, supplemented, suspended, withdrawn or refused according to the procedures as laid down in Annexes 2 to 5;</p>\
</div>\
<div style='margin-left: 30pt; text-indent: -30pt'>\
    <p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>(b)<span style='word-spacing: 18pt'> </span>data obtained in accordance with the vigilance procedure as defined in Article 8;</p>\
</div>\
<div style='margin-left: 30pt; text-indent: -30pt'>\
    <p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>(c)<span style='word-spacing: 18pt'> </span>data relating to clinical investigations referred to in Article 10.</p>\
</div>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>2.  Data shall be forwarded in a standardised format.</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>3.  The measures necessary for the implementation of paragraphs 1 and 2 of this Article, in particular paragraph 1(c), shall be adopted in accordance with the regulatory procedure referred to in Article 6(3).</p>\
<p style='font-style: italic; text-align: center; margin-top: 12pt; margin-btoom: 6pt'>Article 10c</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>Where a Member State considers in relation to a given product or group of products that, in order to ensure protection of health and safety and/or to ensure that public health requirements are observed, such products should be withdrawn from the market, or their placing on the market and putting into service should be prohibited, restricted or subjected to particular requirements, it may take any necessary and justified transitional measures.</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>The Member State shall then inform the Commission and all the other Member States of the transitional measures, giving the reasons for its decision.</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>The Commission shall, whenever possible, consult the interested Parties and the Member States. The Commission shall adopt its opinion, indicating whether the national measures are justified or not. The Commission shall inform all the Member States and the consulted interested Parties.</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; text-align: justify; margin-top: 6pt; margin-bottom: 0pt'>When appropriate, the necessary measures designed to amend non-essential elements of this Directive, by supplementing it, relating to withdrawal from the market, prohibition of placing on the market and putting into service of a certain product or group of products or to restrictions or introduction of particular requirements therefor, shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 6(4). On imperative grounds of urgency, the Commission may use the urgency procedure referred to in Article 6(5).</p>\
<p style='font-family: 'Arial Unicode MS'; font-size: 10pt; font-weight: bold; text-align: left; margin-top: 6pt; margin-bottom: 0pt'>\
<a href='http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31990L0385:EN:NOT'\
    title='31990L0385'\
    target='_blanc'>▼B</a>\
</p>\
